| Ytd | 39.31% | |
| 1y | 372.74% |
| Open | 4.08 | Prev Close | 4.06 | Low | 4.01 | High | 4.21 | Mkt Cap | 230.01M |
| Vol | 144.99K | Avg Vol | 459.27K | EPS | -1.00 | P/E | -4.04 | Forward P/E | -0.82 |
| Beta | 0.95 | Short Ratio | 7.51 | Inst. Own | 84.98% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 4.37 | 200-d Avg | 3.00 | 1yr Est | 5.00 |
PRLD News
Prelude Therapeutics (PRLD) might move higher on growing optimism about its earnings prospects, whic
US stock futures up 0.1%, Dave and Buster's (PLAY) down 13.4% pre-market due to lower earnings;
Prelude Therapeutics (NASDAQ:PRLD) reported quarterly losses of $(0.13) per share which beat the ana
D. Boral Capital analyst Jason Kolbert initiates coverage on Prelude Therapeutics (NASDAQ:PRLD) w
Wall Street analysts changed their outlook on top companies. Truist Securities, Guggenheim, Benchmar
HC Wainwright & Co. analyst Robert Burns maintains Prelude Therapeutics (NASDAQ:PRLD) with a
In lieu of Common Stock to investors who so chose, pre-funded warrants to purchase up to 2,252,252 s
Title: First-in-Class potent and selective oral KAT6A degrader development candidate, PRT13722, driv
Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that
Citizens analyst Reni Benjamin maintains Prelude Therapeutics (NASDAQ:PRLD) with a Market Outperf
Prelude Therapeutics (NASDAQ:PRLD) reported quarterly losses of $(0.20) per share which missed the a
During Thursday, 849 stocks hit new 52-week lows.
Gainers Synthetic Biologics, Inc. (NYSE: SYN) shares climbed 100% to close at $1.00 on Tuesday af